IL-22: A Unique Cytokine in Mucosal Immunity and Tissue Protection

Discovery and Molecular Characteristics of IL-22

Identification and Structural Features

Discovered in 2000, interleukin-22 (IL-22) represents a distinctive member of the IL-10 cytokine family. The human IL-22 gene encodes a 179-amino acid precursor protein that undergoes post-translational processing to yield a 146-amino acid mature secreted form after cleavage of the 33-amino acid signal peptide. Structurally, IL-22 adopts the characteristic four-helix bundle topology common to class II cytokines, with unique spatial configurations that determine its receptor binding specificity.

Receptor Complex and Signaling Pathways

The functional IL-22 receptor consists of a heterodimeric complex formed by IL-22R1 and IL-10R2 subunits. Notably, IL-22R1 serves dual roles as a receptor component for other IL-10 family cytokines including IL-20 and IL-24. Additionally, a soluble decoy receptor termed IL-22 binding protein (IL-22BP) exists that competes with membrane-bound receptors for IL-22 binding, thereby modulating its biological activity. Upon ligand engagement, the receptor complex initiates intracellular signaling primarily through JAK1-mediated phosphorylation and subsequent STAT3 activation, although alternative pathways involving STAT1 and STAT5 have been reported under specific conditions.

Cellular Sources and Regulation of IL-22 Production

Adaptive Immune Cell Producers

CD4+ T helper cell subsets constitute major sources of IL-22 in adaptive immunity. Th1 cells produce IL-22 under IL-12 stimulation, while Th17 cells co-secrete IL-22 with IL-17 when activated by IL-6 and IL-23. The discovery of Th22 cells—a specialized subset producing IL-22 without concomitant IFN-γ, IL-4, or IL-17 secretion—highlighted the diversity of IL-22-producing lymphocytes. Other T cell populations including CD8+ cytotoxic T cells, γδ T cells, and natural killer T (NKT) cells also contribute to IL-22 production, particularly in response to IL-23 stimulation.

Innate Lymphoid Cell Contributors

Group 3 innate lymphoid cells (ILC3s) represent crucial innate sources of IL-22, especially at mucosal surfaces. These tissue-resident lymphocytes rapidly respond to environmental cues through pattern recognition receptors and cytokine signals (notably IL-23), providing early IL-22 production that bridges innate and adaptive immunity. The aryl hydrocarbon receptor (AhR) serves as a master transcriptional regulator of IL-22 expression in both ILC3s and Th22 cells, linking environmental sensing to cytokine production.

Biological Functions and Tissue-Specific Actions

Epithelial Barrier Regulation

Unlike most interleukins that primarily target immune cells, IL-22 exerts its predominant effects on epithelial tissues throughout the body. In skin, gut, and respiratory epithelia, IL-22 induces:
• Antimicrobial peptides (β-defensins 2/3, S100 proteins, lipocalin 2)
• Matrix metalloproteinases (MMP1, MMP3)
• Neutrophil-attracting chemokines (CXCL1, CXCL5, CXCL8)
• Mucin production (MUC1 in intestinal and respiratory epithelia)
• Proliferation-promoting factors (cyclin D1, CDK4)

Simultaneously, IL-22 inhibits terminal differentiation markers in keratinocytes (keratin 1/10, profilaggrin, involucrin), demonstrating its unique capacity to modulate epithelial biology.

Hepatoprotective and Regenerative Effects

In hepatic tissues, IL-22 mediates multiple protective mechanisms:
• Upregulation of anti-apoptotic proteins (BCL-2, BCL-XL, MCL1)
• Induction of acute phase reactants (haptoglobin, serum amyloid A)
• Stimulation of hepatocyte proliferation through cell cycle regulators
• Enhancement of antioxidant defenses against oxidative stress
• Promotion of liver stem cell maintenance and differentiation

These concerted actions position IL-22 as a critical mediator of liver homeostasis and repair following various forms of injury.

Pathophysiological Roles in Human Diseases

Psoriasis Pathogenesis

In psoriatic lesions, IL-22 from infiltrating Th17/Th22 cells and ILCs drives disease pathology through multiple keratinocyte-directed effects:
• Epidermal hyperplasia (acanthosis) via inhibited differentiation
• Disrupted cornification leading to parakeratosis
• Recruitment of neutrophils through chemokine induction
• Tissue remodeling via MMP production
• Amplification of inflammation through IL-20 induction

The centrality of IL-22 in psoriasis pathogenesis has made it an attractive therapeutic target, with several IL-22-neutralizing approaches in preclinical development.

Inflammatory Bowel Disease Paradox

Despite elevated IL-22 levels in inflammatory bowel disease (IBD) patients, impaired mucosal healing persists. This apparent paradox may reflect:
• Counterregulation by IL-22BP limiting bioactive IL-22
• Epithelial resistance mechanisms in chronic inflammation
• Opposing effects of different IL-22-producing cell subsets
• Tissue-specific variations in receptor expression patterns

Understanding these complexities remains crucial for developing effective IL-22-based IBD therapies.

Therapeutic Targeting Opportunities

IL-22 Neutralization Strategies

For conditions with pathogenic IL-22 overactivity (e.g., psoriasis), multiple intervention points exist:
• Direct IL-22 neutralization with monoclonal antibodies
• IL-22BP administration as a natural antagonist
• Blockade of IL-22R1 signaling
• Inhibition of upstream regulators (AhR antagonists)
• Modulation of IL-22-producing cell recruitment

The restricted expression pattern of IL-22R1 offers potential for tissue-specific effects with limited systemic immune modulation.

IL-22 Augmentation Approaches

In settings requiring epithelial protection/regeneration (e.g., mucosal injury, liver diseases), therapeutic strategies include:
• Recombinant IL-22 administration
• IL-22BP inhibition to enhance endogenous IL-22 activity
• Pharmacologic induction of protective IL-22-producing cells
• Combination with tissue-specific growth factors

Ongoing clinical trials are evaluating the safety and efficacy of these approaches in various disease contexts.

Future Perspectives and Challenges

Despite significant progress, key questions remain regarding IL-22 biology:
• Determinants of its tissue-specific pleiotropic effects
• Mechanisms underlying the IL-22/IL-22BP regulatory axis
• Role of IL-22 in tumor microenvironment modulation
• Potential cross-talk with other cytokine systems
• Long-term consequences of therapeutic modulation

Addressing these questions will require advanced model systems integrating epithelial-immune interactions and human translational studies. The development of more specific pharmacological tools and biomarkers will be essential for realizing the full therapeutic potential of IL-22 pathway modulation in diverse clinical contexts.